Losartan
- Atc Codes:C09CA01
- CAS Codes:124750-99-8#114798-26-4
- PHARMGKB ID:124750-99-8#114798-26-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Cosaar, Lanosar, Losartan, Losindia, Malorkatan, Tarnasol; Belgium: Cozaar, Loortan; Bulgaria: Cozaar, Lorista, Lozap, Rasoltan; Cyprus: Cozaar; Czech Republic: Arionecs, Arionex, Cozaar, Lorista, Losacor, Losagen, Losartan, Lozap, Nopretens, Sangona; Denmark: Cozaar, Lorzaar, Losaprex; Estonia: Cozaar, Lorista, Losartan, Lozap, Sartens, Tarnasol; Finland: Cozaar, Losarstad, Losartan, Losatrix, Losindia, Sartonal, Verolos; France: Cozaar; Germany: Barlosan, Coozar, Cozaar, Entrizen, Lorzaar, Losacor, Losafox, Losagrün, Losamat, Losar, Losarcor, Losardim, Losargamma, Losaricca, Losarix, Losartan, Losarto, Losartop, Losindia, Malorkatan, Merisartan, Solarfenium; Greece: Agioart-S, Cozaar, Cozapert, Golasan, Hypozar, Loben, Lorfast, Losadrac, Losalet, Losametan, Losarb, Lozatan, Lyosan, Mozartan, Normatens, Ozarium, Press-Down, Proelsartan, Rabolan, Rapifast, Sartafin, Sitrovin, Tensortan; Hungary: Cozaar; Ireland: Cosartal, Cozaar, Cozatan, Losartan, Lotanos, Lozitar, Myzaar, Solvatan; Italy: Cozaar, Lortaan; Latvia: Cozaar, Lorista, Losartan, Lozap, Sartens, Tarnasol; Lithuania: Cozaar, Covance, Lorista, Losacor, Losargamma, Losartan, Lozap, Sartens, Tarnasol; Luxembourg: Cozaar; Malta: Cozaar, Lopress; Netherlands: Cozaar, Entrizen, Kaliumlosartan, Loridan, Losafox, Losahelm, Losamater, Losanox, Losartan, Lozitan; Poland: Cozaar, Heartam, Lakea, Lorista, Losacor, Losagen, Losahyp, Losarlic, Losartan, Losartic, Lozap, Lozart, Presartan, Rasoltan, Sartamerck, Sarve, Stadazar, Xartan; Portugal: Aratis, Cozaar, Decara, Lortaan, Losartan, Loteak; Romania: Cozaar, Lorista, Losartan, Lozap, Relitaz, Sartens, Talosan; Slovakia: Asortek, Cozaar, Lakea, Lorista, Losarax, Losartan; Slovenia: Cozaar, Lorista, Losartan, Losartic, Lotar, Rasoltan; Spain: Cozaar, Losartan; Sweden: Cozaar, Losaprex, Losarstad, Losartan, Losatrix, Losindia, Lostankal; UK: Cozaar.
North America
Canada: Cozaar; USA: Cozaar.
Latin America
Argentina: Biablan, Cartan, Corticosan, Cozaarex, Enromic, Fensartan, Klosartan, Loctenk, Loplac, Losacor, Losargal, Losarlan, Losartan, Niten, Paxon, Presinor, Tacardia, Tacicul, Temisartan, Troezel, Vasexten; Brazil: Aradois, Corus, Cozaar, Lanzacor, Losartan Potássico, Losartana Potássica, Losartec, Torlós, Valtrian, Zaarpress; Mexico: Bimidal, Cozaar.
Asia
Japan: Nu-Lotan.
Drug combinations
Losartan and Hydrochlorothiazide
Chemistry
Losartan Potassium: C~22~H~22~ClKN~6~O. Mw: 461.00. (1) 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-, monopotassium salt; (2) 2-Butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol, monopotassium salt. CAS-124750-99-8; CAS-114798-26-4 (losartan)(1992).
Pharmacologic Category
Angiotensin II Receptor Antagonists. (ATC-Code: C09CA01).
Mechanism of action
As a selective and competitive nonpeptide angiotensin II receptor antagonist, losartan blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II. Losartan increases urinary flow rate and in addition to being natriuretic and kaliuretic, increases excretion of chloride, magnesium, uric acid, calcium, and phosphate.
Therapeutic use
Treatment of hypertension. Treatment of diabetic nephropathy in type 2 diabetes mellitus (non-insulin-dependent) and history of hypertension. Stroke risk reduction in hypertension and left ventricular hypertrophy.
Pregnancy and lactiation implications
Drugs which act on angiotensin system can cause injury and death to developing fetus when used in 2^nd^ and 3^rd^ trimesters. Use not recommended while breast-feeding.
Unlabeled use
Contraindications
Hypersensitivity to losartan or any component of the formulation.
Warnings and precautions
Angioedema might occur rarely and may involve head and neck (potentially compromising airway) or intestine (presenting with abdominal pain). Hyperkalemia might occur. Renal function deterioration and/or increases in serum creatinine might occur. Use with caution in significant aortic/mitral stenosis, in hepatic impairment, in unstented unilateral/bilateral renal artery stenosis, and with pre-existing renal insufficiency and severe renal impairment. Can cause injury and death to developing fetus when used in 2^nd^ and 3^rd^ trimesters.